Yoo Sang Yoon

Yoo Sang Yoon

Auto-generated profile, based on publicly available information

Yoo Sang Yoon

Department of Thoracic and Cardiovascular Surgery, Busan Paik Hospital, Inje University, Busan, Republic of Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
The development of first-generation immune-checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 ushered in a new era in anticancer therapy. Although immune-checkpoint blockade therapies have shown clinical success, a substantial number of patients yet fail to benefit. Many studies are under way to discover next-generation immunotherapeutic targets. Immunoglobulin superfamily member 1 (IGSF1) is a membrane glycoprotein proposed to regulate thyroid function. Despite containing 12 immunoglobin domains, a possible role for IGSF1, in immune response, remains unknown. Here, our studies revealed that IGSF1 is predominantly expressed in tumors but not normal tissues, and increased expression is observed in PD-L1low non–small cell lung cancer (NSCLC) cells as compared with PD-L1high cells. Subsequently, we developed and characterized an IGSF1-specific human monoclonal antibody, WM-A1, that effectively promoted antitumor immunity and overcame the limitations of first-generation immune-checkpoint inhibitors, likely via a distinct mechanism of action. We further demonstrated high WM-A1 efficacy in humanized peripheral blood mononuclear cells (PBMC), and syngeneic mouse models, finding additive efficacy in combination with an anti–PD-1 (a well-characterized checkpoint inhibitor). These findings support IGSF1 as an immune target that might complement existing cancer immunotherapeutics.

31 August 2022 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
JLJuhyun Lee
Juhyun Lee
SLSung Kwang Lee
Sung Kwang Lee
JWJinhong Wi
Jinhong Wi
YYYoo Sang Yoon
Yoo Sang Yoon
IHIl-Yong Han
Il-Yong Han
YLYang Haeng Lee
Yang Haeng Lee
Juhyun Lee, M.D., Sung Kwang Lee, M.D., Jinhong Wi, M.D., Yoo Sang Yoon, M.D., Il-Yong Han, M.D., Yang Haeng Lee, M.D.. J Chest Surg 2022;55:482-4. https://doi.org/10.5090/jcs.22.017

30 December 2020 in Journal of the Korean Society of Radiology
Verified
Journal Article
Open access
PDF file
JHJi-yeon Han
Ji-yeon Han
KLKi-Nam Lee
Ki-Nam Lee
YYYoo Sang Yoon
Yoo Sang Yoon
JLJihyun Lee
Jihyun Lee
HLHongyeul Lee
Hongyeul Lee
DKDasom Kim
Dasom Kim
한지연, et al. J Korean Soc Radiol. 2020 Dec;82:e18. https://doi.org/10.3348/jksr.2020.0013

17 June 2026
Verified
Other
Open access
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
WM-A1 induces T cell activation in vitro and in vivo.

17 June 2026
Verified
Other
Open access
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
Analysis of IGSF1 expression and the physiological characteristics.

17 June 2026
Verified
Other
Open access
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
Cytokine profile released from PBMCs co-cultured with NCI-H292-IGSF1 O/E cancer cell line.